Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is developing innovative prescription medications to treat fibromyalgia, post-traumatic stress disorder (PTSD), and tension headache, all characterized by inadequate treatment options, dissatisfaction expressed among patients and physicians, and significant expense burden. Tonix leverages the established human safety and pharmacokinetics of known drugs and, through a directed process of repurposing and reformulation, creates products to address important problems that often lack validated animal models or defined molecular targets. For more information, visit the company’s website at www.tonixpharma.com